Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Account Payables (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Change in Account Payables for 10 consecutive years, with $615000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 81.88% year-over-year to $615000.0, compared with a TTM value of -$4.7 million through Sep 2025, down 194.14%, and an annual FY2024 reading of $5.9 million, up 678.98% over the prior year.
  • Change in Account Payables was $615000.0 for Q3 2025 at Spero Therapeutics, up from -$985000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.7 million in Q1 2022 and bottomed at -$5.5 million in Q1 2025.
  • Average Change in Account Payables over 5 years is $12684.2, with a median of $275000.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables skyrocketed 5064.71% in 2024, then plummeted 428.26% in 2025.
  • Year by year, Change in Account Payables stood at -$2.1 million in 2021, then increased by 4.51% to -$2.0 million in 2022, then surged by 113.98% to $275000.0 in 2023, then soared by 342.18% to $1.2 million in 2024, then crashed by 49.42% to $615000.0 in 2025.
  • Business Quant data shows Change in Account Payables for SPRO at $615000.0 in Q3 2025, -$985000.0 in Q2 2025, and -$5.5 million in Q1 2025.